Maurizio Billi among the most influential in Sustainability
Published in: May 19, 2017
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, May 2017 – Maurizio Billi, Eurofarma president, was awarded as one of the most influential Health executives in ‘Sustainability’ category in the “100 Most Influential Persons in Health 2017” prize, organized by Grupo Mídia. The event took place this last Thursday, at the Esporte Clube Sírio’s Noble Hall, in São Paulo.
“This is an important year. We are celebrating 10 years of Itapevi Industrial Complex, one of the best pharmaceutical industrial parks in Latin America, and we are celebrating 45 years of history. I am proud of our relevant position in the sector, since our accomplishments are the result of hard work, dedication, discipline, towards growth, which have always driven us to reinvest in the company itself. We believe and we are absolutely committed with Eurofarma future. I understand that being considered an influential executive is associated to Eurofarma history and accomplishments”, states Maurizio.
In total, the prize paid homage to five professionals in each of its 20 categories, like Quality and Safety, Sustainability, Sectorial Entities, Supplementary Health, Industry, among others. The executive were chosen by public voting, via internet, and by market analysis, performed by Grupo Mídia Editorial Council.
Learn more about our actions by visiting our website http://www.eurofarma.com.br/cartilha-sustentavel/
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br
“This is an important year. We are celebrating 10 years of Itapevi Industrial Complex, one of the best pharmaceutical industrial parks in Latin America, and we are celebrating 45 years of history. I am proud of our relevant position in the sector, since our accomplishments are the result of hard work, dedication, discipline, towards growth, which have always driven us to reinvest in the company itself. We believe and we are absolutely committed with Eurofarma future. I understand that being considered an influential executive is associated to Eurofarma history and accomplishments”, states Maurizio.
In total, the prize paid homage to five professionals in each of its 20 categories, like Quality and Safety, Sustainability, Sectorial Entities, Supplementary Health, Industry, among others. The executive were chosen by public voting, via internet, and by market analysis, performed by Grupo Mídia Editorial Council.
Learn more about our actions by visiting our website http://www.eurofarma.com.br/cartilha-sustentavel/
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br